By Duncan Stark

On September 21, the Federal Circuit handed down its most recent Monsanto patent-related decision, Monsanto Company v. Bowman, reaffirming the company’s intellectual property rights and its licensing and enforcement strategies. This post provides some context for, and a discussion of, the issues raised in this case.

Monsanto invented the herbicide glyphosate in the 1970s (see U.S. Patent #3,799,758) and began selling it under the trade name Roundup in 1973. Roundup enjoyed great commercial success and is still widely used today. Monsanto later invented technology which allowed them to create genetically altered seeds that would grow into plants resistant to glyphosate. These genetically altered seeds, marketed as “Roundup Ready,” have similarly enjoyed great commercial success. Monsanto patents (see, e.g., U.S. Patent #5,352,605) cover the genetically modified seeds, which pass on their glyphosate-resistive properties to subsequent seed generations.

The licensing agreements under which Monsanto commercializes their Roundup Ready seed technology have generally prohibited, among other things, transfer or re-use of genetically altered seed for replanting, effectively requiring that every farmer wanting to plant Roundup Ready seed must, every season, go back to Monsanto to purchase additional seed. This policy has angered many farmers who have traditionally kept seed grown in one season to plant in the next, or purchased seed in bulk from other sources.

Monsanto has disclosed that since 1997 it has filed suit against 145 farmers for patent infringement and proceeded through trial against eleven. A handful of these cases have become high profile patent suits. Continue reading →

Staff Writer

Americans are increasingly turning to software programs to prepare their income tax returns.  But before clicking ‘E-file,’ taxpayers should be aware of a recent line of Tax Court cases indicating that software programs don’t offer the same penalty protections as your friendly, neighborhood accountant.

One penalty provision every taxpayer should be aware of is found in I.R.C. § 6662, the accuracy-related penalty section. This provision says that whenever a taxpayer understates their tax liability because of negligence, the I.R.S. can add a penalty to the taxpayer’s bill equal to 20% of the taxpayer’s deficiency.  I.R.C. §6662(b)(1).  Similarly, anytime a taxpayer substantially understates their tax liability, defined in the internal revenue code as an understatement by the greater of $5,000 or 10% of the liability required to be reported on the taxpayers return, the I.R.S. can assert the same 20% penalty. I.R.C. §6662(b)(2), I.R.C. §6662(d).  When faced with these penalties, taxpayers can argue that they qualify for an exception from the penalty because they had a reasonable cause for the understatement and acted with good faith.  I.R.C. §6664(c).  In determining whether a taxpayer acted with reasonable cause and good faith, a court will look at all the pertinent facts and circumstances. Treas. Reg. § 1.6664-1(b)(1).  Continue reading →

By Julie R. Severson, Ph.D.

At the nexus of technology, business, and free speech an interesting story always seems to percolate.  Well, this summer is no exception; a rift has appeared between the U.S. Supreme Court and the Ninth Circuit on the matter of a state’s right to control commercial speech pertaining to pharmacy records.  Let me explain.  In June, the Supreme Court protected commercial free speech rights in Sorrell v. IMS Health, when in a 6-3 decision it held that Vermont may not restrict data-mining companies from selling pharmacy records revealing “prescriber identifiable data” without prescribers’ consent—despite Vermont’s agenda in passing the legislation in 2007 of lowering the costs of medical services and promoting public health.  (For those who need a 0 to 60 update, such data mining companies often serve as the middle-man between pharmacies and the pharmaceutical industry, buying from the former and selling to the latter records of individual physician prescribing practices so that pharmaceutical companies can fine-tune their commercialization of mostly name brand—as opposed to generic—drugs, and ultimately maximize profit.)  Despite the loophole Vermont provided allowing doctors to opt in and both make their records available for such purposes and receive targeted information based on their prescribing history, the majority remained poignantly sensitive to any ostensible infringement on speech.  Quoting the Second Circuit’s holding, it affirmed that the “First Amendment protects even dry information, devoid of advocacy, political relevance, or artistic expression.”  Sorrell v. IMS Health Inc., — U.S. — at —, 131 S.Ct. 2653, 2666, 180 L.Ed. 2d 544 (2011). 

Continue reading →

Staff Writer

Companies are using the internet to spy on you, and often without your knowledge or consent. Tracking technology has gotten smarter and more intrusive: businesses collect data on websites visited, shopping habits, and even medical conditions. Through the growth of social networking websites and geolocation applications on mobile phones, this data increasingly contains information about your activities in the offline world. This information is most often used to target advertising towards particular users. Should companies be allowed to accumulate unlimited statistics about anyone who uses the internet, or should our privacy be protected in some way?  In a recent report on privacy, the FTC proposed recommendations on protecting consumer privacy, including simplifying consumer choice through the use of a “Do Not Track” option. A “Do Not Track” option could be offered up by the industry or required by legislation.

At least two bills have been proposed that would require a “Do Not Track” option that would require internet browsers to include an opt-out feature that would tell website operators that you do not want to your online movements tracked.

Continue reading →